- Home
- FC vs RNA Comparison
FC vs RNA Comparison
Compare FC & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FC | RNA |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 222.5M |
| IPO Year | 1994 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FC | RNA |
|---|---|---|
| Price | $21.42 | $12.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | $26.00 | ★ $69.26 |
| AVG Volume (30 Days) | 78.0K | ★ 128.0K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $267,067,000.00 | N/A |
| Revenue This Year | $3.15 | $88.12 |
| Revenue Next Year | $4.04 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $11.13 |
| 52 Week High | $26.81 | $73.06 |
Technical Indicators
Market Signals| Indicator | FC | RNA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout FC Franklin Covey Company
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.